Molecular characterization of the recombinant protein RmLTI-BmCG-LTB: Protective immunity against Rhipicephalus (Boophilus) microplus.

Vista sencilla de ítem
dc.contributorBárbara Guimarães Csordas, Programa de Pós-graduacão em Doenças Infecciosa s e Parasitárias/Faculdade de Medicina/Universidad e Federal de Mato Grosso do Sul - UFMS; Rodrigo Casquero Cunha, Programa de Pós-graduação em Biotecnologia/Universidade Federal de Pelotas - UFPEL; Marcos Valério Garcia, Bolsista de Pós-Doutorado, Fundação de Apoio ao Desenvolvimento do Ensino, Ciência e Tecnologia do Estado de Mato Grosso do Sul; Sérgio Silva da Silva, Laboratório de Doenças Parasitárias/Faculdade de Medicina Veterinária/Universidade Federal de Pelotas - UFPEL; Fábio Leivas Leite, Programa de Pós-graduação em Biotecnologia/Universidade Federal de Pelotas - UFPEL; RENATO ANDREOTTI E SILVA, CNPGC.
dc.creatorCSORDAS, B. G.
dc.creatorCUNHA, R. C.
dc.creatorGARCIA, M. V.
dc.creatorSILBA, S. da S.
dc.creatorLEITE, F. L.
dc.creatorANDREOTTI, R.
dc.date2018-12-20T23:39:08Z
dc.date2018-12-20T23:39:08Z
dc.date2018-12-18
dc.date2018
dc.date2018-12-20T23:39:08Z
dc.date.accessioned2026-07-07T03:40:43Z
dc.descriptionThe bovine tick Rhipicephalus (Boophilus) microplus is found in several tropical and subtropical regions of the world. This parasite transmits pathogens that cause disease, such as babesiosis ( Babesia bovis and B . bigemina ) and anaplasmosis (Anaplasma marginale). Tick infestations cause enormous livestock losses, and controlling tick infestations and the transmission of tick-borne diseases remains a challenge for the livestock industry. Because the currently available commercial vaccines offer only partial protection against R. (B.) microplus, there is a need for more efficient vaccines. Several recombinant antigens have been evaluated using different immunization strategies, and they show great promise. This work describes the construction and immunological characterization of a multi-antigen chimera composed of two R. (B.) microplus antigens (RmLTI and BmCG) and one Escherichia coli antigen (B subunit, LTB). The immunogenic regions of each antigen were selected and combined to encode a single polypeptide. The gene was cloned and expressed in E . coli . For all of the experiments, two groups (treated and control) of four Angus heifers (3?6 months old) were used. The inoculation was performed via intramuscular injection with 200 μ g of purified recombinant chimeric protein and adjuvated. The chimeric protein was recognized by specific antibodies against each subunit and by sera from cattle inoculated with the chimera. Immuni-zation of RmLTI-BmCG- LTB cattle reduced the number of adult female ticks by 6.29% and vaccination of cattle with the chimeric antigen provided 55.6% efficacy against R . (B.) microplus infestation. The results of this study indicate that the novel chimeric protein is a potential candidate for the future development of a more effective vaccine against R . (B.) microplus .
dc.identifierPLOS ONE, February, 2018
dc.identifierhttp://www.alice.cnptia.embrapa.br/alice/handle/doc/1101907
dc.identifierdoi.org/10.1371/journal.pone.0191596
dc.identifier.urihttp://hdl.handle.net/123456789/440621
dc.languageeng
dc.rightsopenAccess
dc.subjectRhipicephalus
dc.subjectRhipicephalus microplus
dc.subjectCattle
dc.subjectParasites
dc.subjectPathogens
dc.subjectBabesiosis
dc.subjectAnaplasmosis
dc.titleMolecular characterization of the recombinant protein RmLTI-BmCG-LTB: Protective immunity against Rhipicephalus (Boophilus) microplus.
dc.typeArtigo de periódico

Archivos

Colecciones

Embrapa Ganado Vacuno (CNPGC)